Market Overview

UPDATE: Bank of America Reduces PO to $34 on Questcor Pharmaceuticals on Probe

Related QCOR
BioTime CEO Explains What Could Happen To Stem Cell Research And The Company Under A New Guard In Washington
Mallinckrodt Is No Valeant-Philidor Situation, Morgan Stanley Says

Bank of America reiterated its Buy rating on Questcor Pharmaceuticals (NASDAQ: QCOR) but lowered its price objective from $45 to $34.

Bank of America commented, "Today Questcor announced in an 8-K that the US government has launched an investigation regarding the company's promotional practices. No other details were provided. Our conversation with CEO Don Bailey did not yield further visibility. The negative impact could be exacerbated by the lack of details provided by the company on today's news as well as last week's news of a change in language on Aetna's coverage policy for Acthar. While there are a wide range of potential outcomes, we now conservatively assume a fine equal to 2012 revenues ($463mn)… We also assume more cautious marketing activities could lead to a more modest revenue growth rate."

Questcor Pharmaceuticals closed at $20.68 on Friday.

Latest Ratings for QCOR

May 2014MizuhoDowngradesBuyNeutral
May 2014PiperJaffrayDowngradesOverweightNeutral
Apr 2014JefferiesDowngradesBuyHold

View More Analyst Ratings for QCOR
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (QCOR)

View Comments and Join the Discussion!

Partner Center